• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Blue Water Vaccines Inc.

    8/29/22 4:36:41 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BWV alert in real time by email
    SC 13D 1 cincinnaticornerstoneinvesto.htm CINCINNATI CORNERSTONE INVESTORS BWV I, LLC - SCHEDULE 13D Converted by EDGARwiz



    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549


    SCHEDULE 13D

    (Rule 13d-101)


    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND

    AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)


    Under the Securities Exchange Act of 1934

    (Amendment No. )*


    Blue Water Vaccines, Inc.

    (Name of Issuer)

    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

    09610B108

    (CUSIP Number)

    Douglas Groh

    Representative of the Manager

    Cincinnati Cornerstone Investors BWV I, LLC

    c/o Cincinnati Cornerstone Capital, LLC

    2900 Reading Road, Suite 410

    Cincinnati, Ohio 45206


    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    August 29, 2022

    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).












    -

    CUSIP No. 09610B108

    13D

    Page 2 of 8 Pages



    1

    NAME OF REPORTING PERSON

    Cincinnati Cornerstone Investors BWV I, LLC


    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) ¨

    3

    SEC USE ONLY


    4

    SOURCE OF FUNDS

    OO


    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ohio


    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

    3,111,201


    8

    SHARED VOTING POWER

    0


    9

    SOLE DISPOSITIVE POWER

    3,111,201


    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON

    3,111,201

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    22.9%


    14

    TYPE OF REPORTING PERSON

    OO















    -

    CUSIP No. 09610B108

    13D

    Page 3 of 8 Pages



    1

    NAME OF REPORTING PERSON

    Cincinnati Cornerstone Capital, LLC


    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨
    (b) ¨

    3

    SEC USE ONLY


    4

    SOURCE OF FUNDS

    OO


    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ohio


    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

    3,111,201


    8

    SHARED VOTING POWER

    0


    9

    SOLE DISPOSITIVE POWER

    3,111,201


    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON

    3,111,201

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    22.9%


    14

    TYPE OF REPORTING PERSON

    OO















    -

    CUSIP No. 09610B108

    13D

    Page 4 of 8 Pages



    Item 1.

    Security and Issuer.


    Item 1 is of this Schedule 13D is hereby amended and restated as follows:


    This Statement of Beneficial Ownership on Schedule 13D (this “Statement”) relates to the Common Stock, $0.00001 par value per share (the “Common Stock”), of Blue Water Vaccines, Inc., a Delaware corporation (the “Company”), which has its principal executive offices located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.  The Common Stock is listed on the Nasdaq Capital Market under the symbol “BWV.”


    Item 2.

    Identity and Background.


    Item 2 is of this Schedule 13D is hereby amended and restated as follows:


    This Statement is filed by Cincinnati Cornerstone Investors BWV I, LLC, an Ohio limited liability company (“CCI BWV”), which is a pooled investment vehicle, and Cincinnati Cornerstone Capital, LLC, an Ohio limited liability company (“CCC”), which is a private fund adviser exempt from registration and the manager and a member of CCI BWV.  As manager of CCI BWV, CCC has the right to control the voting and disposition of the Common Stock held by CCI BWV.  CCI BWV and CCC sometimes are referred to herein individually as a “Reporting Person” and collectively as the “Reporting Persons.”  The Reporting Persons are filing this Statement jointly. Neither the fact of this filing nor anything contained herein shall be deemed to be an admission by any of the Reporting Persons that they constitute a “group.”


    The business address of each of the Reporting Persons is 2900 Reading Road, Suite 410, Cincinnati, Ohio 45206.


    Upon the closing of the Company’s initial public offering on February 23, 2022, CCI BWV acquired direct ownership, and CCC acquired indirect ownership through CCI BWV, of 3,611,201 shares of Common Stock through the previously agreed upon automatic conversion of 735,632 shares of Series Seed Preferred Stock of the Company held by CCI BWV (the “Series Seed Preferred Stock”).  


    The directors and executive officers of CCC are set forth on Schedule I hereto.  Schedule I sets forth each such person’s:  (i) name, (ii) business address, (iii) present principal occupation of employment and the name, principal business and address of any corporation or other organization in which such employee is employed, and (iv) citizenship.


    Neither of the Reporting Persons nor any of their partners, managers, officers or other controlling persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).


    Neither of the Reporting Persons nor any of their partners, managers, officers or other controlling persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


    Item 3.

    Source and Amount of Funds or Other Consideration.


    Item 3 is of this Schedule 13D is hereby amended and restated as follows:


    The transaction reported herein was a distribution to the members of CCI BWV for no consideration.













    -

    CUSIP No. 09610B108

    13D

    Page 5 of 8 Pages



    Item 4.

    Purpose of Transaction.


    Item 4 is of this Schedule 13D is hereby amended and restated as follows:


    The transaction reported herein reflects a distribution of Company Common Stock pursuant to a pro rata distribution by CCI BWV on August 25, 2022 to its members for no consideration.


    Item 5.

    Interest in Securities of the Issuer.


    Item 5 is of this Schedule 13D is hereby amended and restated as follows:


    (a)  The Reporting Persons beneficially own 3,111,201 shares of Common Stock, which represents approximately 22.9% of the Company’s outstanding shares of Common Stock.  All of the Common Stock is beneficially owned directly by CCI BWV, and indirectly by CCC, the manager and a member of CCI BWV, through its control of CCI BWV.


    The percentage ownership of shares of Common Stock by the Reporting Person as set forth in this Statement is based on the 13,579,399 shares of Common Stock reported by the Company as outstanding as of August 15, 2022 in its Form 10-Q filed with the Securities and Exchange Commission pursuant to on August 15, 2022.


    (b)  CCC, as the manager of CCI BWV, has the sole power to direct the vote and the disposition of the Common Stock held by CCI BWV.


    (c)  The sole transaction by the Reporting Persons in the Common Stock in the last 60 days was the distribution of Company Common Stock pursuant to a pro rata distribution by CCI BWV to its members for no consideration on August 25, 2022.


    (d)  No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock beneficially owned by any Reporting Person; however, CCC, as the manager of CCI BWV, has the right from time to time to cause CCI BWV to make distributions to the members of CCI BWV of any such dividends or proceeds received by BWV.  As of the date hereof, no member of CCI BWV other than CCC has the right to receive beneficial ownership of 5% or more of the Company’s Common Stock by reason of any distribution from CCI BWV.


    (e)  Not applicable.












    -

    CUSIP No. 09610B108

    13D

    Page 6 of 8 Pages



    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.


    Item 6 is of this Schedule 13D is hereby amended and restated as follows:


    Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, which agreement is set forth on the signature page to this Statement.


    Item 7.

    Material to Be Filed as Exhibits.


    Item 7 is of this Schedule 13D is hereby amended and restated as follows:


    Joint Filing Agreement among the Reporting Persons (set forth on the signature page to this Statement and incorporated herein by reference).













    -

    CUSIP No. 09610B108

    13D

    Page 7 of 8 Pages



    SIGNATURES


    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct.


    In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Statement on Schedule 13D with respect to the Common Stock of the Company.


    Dated:  August 29, 2022


    CINCINNATI CORNERSTONE INVESTORS BWV I, LLC




    /s/  Douglas Groh


    Douglas Groh

    Representative of the Manager




    CINCINNATI CORNERSTONE CAPITAL, LLC




    /s/  Douglas Groh


    Douglas Groh

    President and Chief Executive Officer
















    -

    CUSIP No. 09610B108

    13D

    Page 8 of 8 Pages


    Schedule 1


    Directors and Executive Officers of Cincinnati Cornerstone Capital, LLC


    Information regarding each director and executive officer of Cincinnati Cornerstone Capital, LLC (each of whom is a U.S. citizen) is set forth below:


    Name, Title

    Address

    Principal Occupation

    Douglas Groh, President & CEO, Board Member

    2900 Reading Rd., Suite 410

    Cincinnati, OH 45206

    President & CEO

    Cincinnati Cornerstone Capital, LLC

    2900 Reading Rd., Suite 410

    Cincinnati, OH 45206





    Get the next $BWV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

    CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:BWV) ("Onconetix" or the "Company") today issued the following shareholder letter from the Company's Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shifts and notable achievements, all aimed at enhancing the value we bring to you as our shareholders. To reflect our recent achievements and renewed oncology focus, we have rebranded as Onconet

    12/19/23 7:00:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

    CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

    12/18/23 7:00:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

    CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company"), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the "Proposed Transaction"). This latest announcement is part of the Company's new business strategy focusing on oncology. The Company plans to commercialize therapeutics, diagnostics and clinician services, which will serve as the foundation for the Company's future operations. The Proposed Transaction furthers a shift in business strategy driven by BWB's decision to align with both the market value drivers provided by its new oncolog

    11/2/23 7:00:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    SEC Filings

    View All

    SEC Form S-1 filed by Blue Water Biotech Inc.

    S-1 - Onconetix, Inc. (0001782107) (Filer)

    2/14/24 5:06:02 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Blue Water Biotech Inc.

    PRE 14A - Onconetix, Inc. (0001782107) (Filer)

    2/14/24 5:04:25 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Biotech Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    2/13/24 8:24:20 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Singh Ajit

    3 - Onconetix, Inc. (0001782107) (Issuer)

    2/16/24 4:05:21 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Meier Thomas

    3 - Onconetix, Inc. (0001782107) (Issuer)

    2/16/24 4:05:11 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Schiess Ralph claimed ownership of 269,749 shares (SEC Form 3)

    3 - Onconetix, Inc. (0001782107) (Issuer)

    1/3/24 4:05:49 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    Leadership Updates

    Live Leadership Updates

    View All

    Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

    CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately. Dr. Campbell has also joined the Company's board of directors. Dr. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals, health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott

    10/10/23 9:00:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

    CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company's Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men's Health issues, including benign prostatic hyperplasia ("BPH"). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies. Dr. Newmark's appointment will support Blue Water's upcoming launch of ENTADFI® and he will work closely with Blue Water management

    4/26/23 3:44:02 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

    CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development. Mr. Jaeger brings over 25 years of biopharmaceutical experience to the BWV team, from start-up to large global pharma with significant pre-launch, launch, and in-market commercialization experience. His background in R&D, Medical Affairs, Business Development, and throughout Commercial Operations provides a broad world view and an understanding of varying perspectives. Mr. Jaeger has a wide r

    2/6/23 10:15:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    Financials

    Live finance-specific insights

    View All

    Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

    CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

    12/18/23 7:00:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

    CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia ("BPH") asset, ENTADFI®. "Blue Water's recent growth is highlighted by our acquisition of ENTADFI®, as well as our subsequent rebranding initiative and name change to reflect our transiti

    5/12/23 6:32:51 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

    Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call Today, April 20th, at 8:30am EDT to Discuss Asset Purchase and Company Transformation CINCINNATI, April 20, 2023 (GLOBE NEWSWIRE) --  Blue Water Vaccines Inc. ("BWV" or "Blue Water" or the "Company"), today announced the signing of an Asset Purchase Agreement (the "Agreement") with Veru Inc. ("Veru") for the purchase of ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia ("BPH") that counteracts negative sexual side effects seen in men on alternative BPH therapies. Unde

    4/20/23 7:30:00 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BWV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)

    SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

    1/26/24 6:01:11 AM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)

    SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

    1/2/24 1:13:20 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Blue Water Biotech Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    12/27/23 6:34:55 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care